Hindes R G, Willey S H, Eliopoulos G M, Rice L B, Eliopoulos C T, Murray B E, Moellering R C
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Antimicrob Agents Chemother. 1989 Jul;33(7):1019-22. doi: 10.1128/AAC.33.7.1019.
Several antimicrobial regimens were evaluated in the treatment of experimental enterococcal endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant strain of Enterococcus faecalis. Ampicillin alone cleared bacteremia in the majority of rats and reduced titers of bacteria within vegetations (6.84 versus 8.80 log10 CFU/g in controls) but did not sterilize valves. Ampicillin-sulbactam combinations, vancomycin, daptomycin, and imipenem each reduced residual bacterial titers within vegetations to 4.01 log10 CFU/g or less; in 26 to 43% of animals receiving 5 days of therapy, titers of bacteria were reduced to undetectable levels. In a separate experiment, rats received ampicillin-sulbactam, daptomycin, or vancomycin for 10 days and were then observed for 10 days after termination of therapy for evidence of relapse. In surviving rats, valves remained sterile in four of five rats treated with ampicillin-sulbactam, in five of seven treated with daptomycin, but in only one of eight receiving vancomycin.
对几种抗菌治疗方案进行了评估,以治疗由一株产β-内酰胺酶、对庆大霉素高度耐药的粪肠球菌引起的实验性肠球菌心内膜炎。单独使用氨苄西林可使大多数大鼠的菌血症清除,并降低赘生物内的细菌滴度(对照组为8.80 log10 CFU/g,而此处为6.84 log10 CFU/g),但未能使瓣膜无菌。氨苄西林-舒巴坦联合用药、万古霉素、达托霉素和亚胺培南各自将赘生物内的残余细菌滴度降低至4.01 log10 CFU/g或更低;在接受5天治疗的动物中,26%至43%的动物细菌滴度降至检测不到的水平。在另一项实验中,大鼠接受氨苄西林-舒巴坦、达托霉素或万古霉素治疗10天,然后在治疗终止后观察10天,以寻找复发证据。在存活的大鼠中,接受氨苄西林-舒巴坦治疗的五只大鼠中有四只瓣膜保持无菌,接受达托霉素治疗的七只大鼠中有五只瓣膜保持无菌,但接受万古霉素治疗的八只大鼠中只有一只瓣膜保持无菌。